Extra support for teens in obesity treatment
Part of Hormones & metabolism clinical trials.
This study is for teens aged 12–17 who are already being offered weight-loss medications. It adds extra support to see if that helps them do better with treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 12 and 17 years old.
- Your doctor has offered you one of two weight-loss medications called liraglutide or semaglutide as part of your clinic's usual care.
- Your family agrees to take part in the study.
- You do not have a serious eating disorder that needs treatment now or has been treated in the last 6 months.
- You do not have certain other medical conditions (like severe psychiatric disorders, genetic syndromes, or unstable hormone problems) that could affect the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a digital support system (a mobile app) to help children and families with obesity treatment. You may be able to use the app alongside the usual care plan if you meet the study’s age, health, and communication requirements.
This study looks at what helps or drives weight changes in children and teens with obesity. You may be asked about growth and body changes to better understand why weight changes happen and how to manage them.
This trial tests a GLP-1 medication (a drug that helps control appetite and blood sugar) combined with a lifestyle program for teens with severe obesity. The goal is to see if this approach can improve overall health and well-being.
This trial studies how the body adapts to weight loss in teens with obesity. You will either get a behavioral lifestyle program alone or with a weight loss medication called semaglutide.
This study tests whether a medication that helps with weight loss, called a GLP-1 agonist, can also change how the brain works. It is for teenagers (12-18) and adults (30-45) with obesity.
This trial studies whether semaglutide (a once-weekly injection) helps adolescents with a specific genetic form of obesity lose weight. It is for teens who are already being prescribed semaglutide as part of their regular care.
Hear when a new Childhood Obesity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.